Skip to main content
SpringerLink
Log in

Prostate cancer: active surveillance may prove organisationally impossible

  • Letter to the Editor
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Tormey WP (2014) The complexity of PSA interpretation in clinical practice. Surgeon 12:323–327. doi:10.1016/j.surge.2014.04.003

    Article  PubMed  Google Scholar 

  2. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/prostate/incidence/uk-prostate-cancer-incidence-statistics#age (Accessed 18 Sept 2014)

  3. National Cancer Registry Ireland. Cancer factsheet prostate. Updated December 2013. http://www.ncri.ie/sites/ncri/files/factsheets/FACTSHEET_prostate.pdf

  4. Singh AK, Kruecker J, Xu S, Glossop N, Guion P, Ullman K, Choyke PL, Wood BJ (2008) Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. BJU Int 101:841–845

    Article  PubMed Central  PubMed  Google Scholar 

  5. Nice (National Institute for Health and Care Excellence). Guidelines [CG175] (2014). http://www.nice.org.uk/Guidance/CG175 (Accessed 20 Sept 2014)

  6. Schroder FH, Hugosson J, Roobol MJ, For the ERSPC Investigators et al (2014) Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384(9959):2027–2035. doi:10.1016/S0140-6736(14)60525-0

    Article  PubMed Central  PubMed  Google Scholar 

  7. Andriole GL, Crawford ED, Grubb RL 3rd et al (2012) Prostate cancer screening in the randomised prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104:125–132

    Article  PubMed Central  PubMed  Google Scholar 

  8. Murphy DG, Ahlering T, Catalona EJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wootten A, Walsh PC, Costello AJ (2014) The Melbourne Consensus Statement on the early detection of prostate cancer. BJU Int 113:186–188. doi:10.1111/bju.12556

    Article  PubMed  Google Scholar 

  9. Ahmed HU (2014) Prostate cancer: Melbourne consensus- noble but misguided. Nat Rev Urol 11:250–251. doi:10.1038/nrurol.2014.65

    Article  PubMed  Google Scholar 

  10. http://www.bjuinternational.com/bjui-blog/the-melbourne-consensus-statement-on-prostate-cancer-testing/ (Accessed 20 Jan 2015)

  11. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, Holmberg L, Kantoff P, Konety BR, Murad MH, Penson DF, Zietman AL (2013) Early detection of prostate cancer: AUA guideline. J Urol 190:419–426. doi:10.1016/j.uro.2013.04.119

    Article  PubMed Central  PubMed  Google Scholar 

  12. Gorin MA, Eldefrawy A, Ekwenna O et al (2012) Active surveillance for low-risk prostate cancer: knowledge, acceptance and practice among urologists. Prostate Cancer Prostatic Dis 15:177–181

    Article  CAS  PubMed  Google Scholar 

  13. Azmi A, Dillon RA, Borghesi S, Dunne M, Power RE, Marignol L, O’Neill BD (2014) Active surveillance for low-risk prostate cancer: diversity of practice across Europe. Ir J Med Sci (Epub ahead of print)

  14. Schoots IG, Petrides N, Giganti F, Bokhurst LP, Rannikko A, Klotz L, Villers A, Hugosson J, Moore CM (2014) Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. Eur Urol. doi:10.1016/j.eururo.2014.10.050

    Google Scholar 

  15. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level of ≤4.0 ng per millilitre. N Engl J Med 350:2239–2246

    Article  CAS  PubMed  Google Scholar 

  16. Klotz L (2005) Active surveillance for low-risk prostate cancer: developments to date. Eur Urol 47:16–21

    Article  PubMed  Google Scholar 

  17. Forde JC, Daly PJ, White S et al (2014) A single centre experience of active surveillance as management strategy for low-risk prostate cancer in Ireland. Ir J Med Sci 183:377–382

    Article  CAS  PubMed  Google Scholar 

  18. Irving G, Holden J (2011) Calling time on the 10-minute consultation. Br J Gen Pract 62:238–239

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chemical Pathology, Beaumont Hospital, Dublin 9, Ireland

    W. P. Tormey

  2. Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland, UK

    W. P. Tormey

Authors
  1. W. P. Tormey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. P. Tormey.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tormey, W.P. Prostate cancer: active surveillance may prove organisationally impossible. Ir J Med Sci 184, 715–717 (2015). https://doi.org/10.1007/s11845-015-1274-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-015-1274-9

Keywords

Search

Navigation